Huang and co-workers [353] evaluated the delivery of human GDNF (hGDNF)-lactoferrin modified nanoparticles in a rotenone-induced chronic Parkinson’s model, concluding that the formulation can be used as a long-term therapy for the treatment of neurogenerative diseases [353]. This evidence concerns the gene GDNF and Parkinsonism.